Clinical trialCLINICALTRIALSMar 27
New Clinical Trial: A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors (NCT04482309)
Researchers are testing a cancer drug called trastuzumab deruxtecan (T-DXd) in patients with several types of rare and uncommon cancers that have a specific protein marker called HER2. The study includes seven different cancer types in the first part, including bladder, bile duct, cervical, uterine, ovarian, and pancreatic cancers. This drug has already shown promise in breast and stomach cancers, and doctors want to see if it works in these other cancer types too.
WHY IT MATTERSThis trial offers patients with HER2-positive rare cancers like biliary tract, cervical, endometrial, ovarian, and pancreatic cancer access to a targeted therapy that has demonstrated effectiveness in other cancer types—potentially providing a new treatment option where few exist.